Moleculin Biotech (MBRX) Shares Outstanding (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Shares Outstanding (Entity) of $1.2 million for Q4 2025, up 776.45% year-over-year from $135156.0 in Q4 2024, and down 20.61% quarter-over-quarter from $1.5 million in Q3 2025.
Moleculin Biotech (MBRX) Shares Outstanding (2015 - 2026) Analysis & Trends
Moleculin Biotech's Shares Outstanding (Entity) history runs 11 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 776.45% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 776.45% YoY), while the FY2025 annual figure was $1.2 million, up 776.45% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $1.2 million, down from $1.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.5 million in Q3 2025, with the low at $58159.0 in Q1 2021.
- The 5-year median for Shares Outstanding (Entity) is $79470.0 (2023), against an average of $252028.6.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) advanced 0.17% in 2022, then jumped 1142.69% in 2025.
- Moleculin Biotech's Shares Outstanding (Entity) stood at $76213.0 in 2021, then grew by 0.17% to $76345.0 in 2022, then rose by 16.71% to $89101.0 in 2023, then soared by 51.69% to $135156.0 in 2024, then soared by 776.45% to $1.2 million in 2025.
- Business Quant data shows MBRX's Shares Outstanding (Entity) at $1.2 million in Q4 2025, $1.5 million in Q3 2025, and $621056.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | 5.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.68 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | 621,056.00 |
| Mar 31, 2025 | 373,751.00 |
| Dec 31, 2024 | 137,720.00 |
| Sep 30, 2024 | 148,571.00 |
| Jun 30, 2024 | 101,730.00 |
| Mar 31, 2024 | 98,647.00 |
| Dec 31, 2023 | 79,024.00 |
| Sep 30, 2023 | 79,495.00 |
| Jun 30, 2023 | 79,174.00 |
| Mar 31, 2023 | 76,670.00 |
| Dec 31, 2022 | 76,282.00 |
| Sep 30, 2022 | 76,344.00 |
| Jun 30, 2022 | 76,225.00 |
| Mar 31, 2022 | 76,213.00 |
| Dec 31, 2021 | 71,673.00 |
| Sep 30, 2021 | 76,200.00 |
| Jun 30, 2021 | 75,875.00 |